Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31516173 | 1.00 | TRPA1 (0.45) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL12159671 | 1.00 | TRPA1 (0.45) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL18644147 | 1.00 | TRPA1 (0.45) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL664164 | 0.82 | CA1 (0.54) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL20522795 | 0.82 | CA1 (0.54) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL27732658 | 0.81 | TRPA1 (0.45) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL12166555 | 0.81 | TRPA1 (0.40) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL3479883 | 0.81 | TRPA1 (0.45) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL24920330 | 0.80 | — | — | |
| SCHEMBL13924883 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0392317-B1 | Benzimidazoles, drugs containing these compounds and process for their preparation | THOMAE GMBH DR K (DE) | 1996-01-03 | — | — | EP | claimed |
| EP-3257872-B1 | ORIENTATION MATERIAL AND RETARDATION MATERIAL | NISSAN CHEMICAL CORP (JP) | 2020-04-22 | — | — | EP | disclosed |
| US-10570248-B2 | Cured film formation composition, orientation material, and retardation material | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2020-02-25 | — | — | US | disclosed |
| US-20180112032-A1 | CURED FILM FORMATION COMPOSITION, ORIENTATION MATERIAL, AND RETARDATION MATERIAL | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2018-04-26 | — | — | US | disclosed |
| US-20180112032-A1 | CURED FILM FORMATION COMPOSITION, ORIENTATION MATERIAL, AND RETARDATION MATERIAL | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2018-04-26 | — | — | US | disclosed |
| EP-3257872-A1 | CURED-FILM-FORMING COMPOSITION, ALIGNMENT MATERIAL, AND PHASE DIFFERENCE MATERIAL | Nissan Chemical Industries, Ltd. (JP) | 2017-12-20 | — | — | EP | disclosed |
| WO-2016002722-A1 | ALIGNMENT MATERIAL, PHASE-DIFFERENCE MATERIAL, AND CURED FILM–FORMING COMPOSITION | 日産化学工業株式会社 | 2016-01-07 | — | — | WO | disclosed |
| US-9223211-B2 | Photosensitive resin compositions, processes for preparing cured films, the resulting cured films, organic EL display devices and liquid crystal display devices | FUJIFILM CORPORATION (JP) | 2015-12-29 | — | — | US | disclosed |
| US-9223211-B2 | Photosensitive resin compositions, processes for preparing cured films, the resulting cured films, organic EL display devices and liquid crystal display devices | FUJIFILM CORPORATION (JP) | 2015-12-29 | — | — | US | disclosed |
| US-9072676-B2 | Cyclohexyl carbamate compounds as skin and/or hair lightening actives | SYMRISE AG (DE) | 2015-07-07 | — | — | US | disclosed |
| US-8193372-B2 | Phosphothiophene and phosphothiazole HCV polymerase inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| EP-2389922-A1 | Cyclohexyl carbamate compounds as anti-ageing actives | Symrise AG (DE) | 2011-11-30 | — | — | EP | disclosed |
| WO-2010122178-A2 | CYCLOHEXYL CARBAMATE COMPOUNDS AS SKIN AND/OR HAIR LIGHTENING ACTIVES | SYMRISE GMBH & CO. KG (DE) | 2010-10-28 | — | — | WO | disclosed |
| US-20100233123-A1 | PHOSPHOTHIOPHENE AND PHOSPHOTHIAZOLE HCV POLYMERASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| EP-1896557-B1 | FLAVOR AND FRAGRANCE COMPOSITION | TAKASAGO PERFUMERY CO LTD (JP) | 2010-05-05 | — | — | EP | disclosed |
| US-20090275669-A1 | Flavor and fragrance composition | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-11-05 | — | — | US | disclosed |
| EP-1896557-A1 | FLAVOR AND FRAGRANCE COMPOSITION | Takasago International Corporation (JP) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006137556-A1 | FLAVOR AND FRAGRANCE COMPOSITION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-12-28 | — | — | WO | disclosed |
| US-5864043-A | CARDIOVASCULAR DISORDERS AND ANGIOTENSIN ANTAGONIST | KARL THOMAE GMBH (DE) | 1999-01-26 | — | — | US | disclosed |
| US-5541229-A | ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570248-B2 | Cured film formation composition, orientation material, and retardation material | C5, C1S, C1R | TRPA1 875/4885TRPM8 4778/4885CA1 1217/4885 |
| US-20090275669-A1 | Flavor and fragrance composition | TAS2R40, TAS2R1, TAS2R50 | TRPA1 32/4885TRPM8 57/4885CA1 4304/4885 |
| US-20100233123-A1 | PHOSPHOTHIOPHENE AND PHOSPHOTHIAZOLE HCV POLYMERASE INHIBITORS | PPP3CB, POLR2E, PSAT1 | TRPA1 2919/4885TRPM8 4624/4885CA1 4370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.